A drug screening toolkit based on the –1 ribosomal frameshifting of SARS-CoV-2
Yanqiong Chen,
Huan Tao,
Silan Shen,
Zhiyong Miao,
Lili Li,
Yongqian Jia,
Hu Zhang,
Xiufeng Bai,
Xinyuan Fu
Affiliations
Yanqiong Chen
Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China; National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
Huan Tao
Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China
Silan Shen
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China
Zhiyong Miao
Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China
Lili Li
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China
Yongqian Jia
Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China
Hu Zhang
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China
Xiufeng Bai
Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China; Corresponding author.
Xinyuan Fu
Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China
The –1 ribosomal frameshifting is vital for the translation of the open reading frame (ORF)1b in SARS-CoV-2. The products of ORF1b participate in viral replication. Therefore, changing the frameshift frequency reduces the survival of the virus. This study aimed to successfully develop a toolkit for screening antiviral drugs. Finally, the FDA-approved drug library was screened, revealing that ivacaftor and (–)-Huperzine A worked well in changing the –1 ribosomal frameshifting of SARS-CoV-2 in vitro.
